1.87
1.87 (0%)
As of Feb 14, 2025
Maia Biotechnology, Inc. [MAIA]
Source:
Company Overview
Maia Biotechnology, Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 ‘-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity.
| Country | United States |
| Headquarters | chicago, illinois |
| Phone Number | (312) 416-8592 |
| Industry | manufacturing |
| CEO | Vlad Vitoc |
| Website | www.maiabiotech.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-17 |
| Net Income | $-23.3 |
| Net Cash | $2.5 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -262.4% |
| Profit as % of Stockholder Equity | -639.8% |
Management Effectiveness
| Return on Equity | -639.8% |
| Return on Assets | -229% |
| Turnover Ratio | |
| EBITA | $-17 |
Balance Sheet and Cash Flow Measures
| Total Assets | $10.2 |
| Total Liabilities | $6.5 |
| Operating Cash Flow | $-15.7 |
| Investing Cash Flow | |
| Financing Cash Flow | $18.2 |
